Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hengrui Medicine Approved to Market Novel HER2 Cancer Drug in China

publication date: Aug 23, 2018

Jiangsu Hengrui Medicine was awarded China approval of a novel treatment for HER2-positive cancer as a second-line therapy. Pyrotinib, a dual EGFR/HER2 dual tyrosine kinase inhibitor, was conditionally approved after it improved Overall Response Rate and more than doubled Progression-Free Survival in a Phase II trial in patients with HER2-positive breast cancer. China conducted a priority review of the drug. Hengrui has already started a China Phase III trial of pyrotinib in the same patient population and an early US trial in solid tumors. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.